Single-Dose Pharmacokinetics of Once-Daily Cyclobenzaprine Extended Release 30 mg versus Cyclobenzaprine Immediate Release 10 mg Three Times Daily in Healthy Young Adults

Clinical Drug Investigation ◽

10.2165/0044011-200828120-00007 ◽

2008 ◽

Vol 28 (12) ◽

pp. 793-801 ◽

Author(s):

Mona Darwish ◽

Edward T Hellriegel ◽

Fang Xie

Keyword(s):

Young Adults ◽

Single Dose ◽

Extended Release ◽

Immediate Release ◽

Download Full-text

Comparison of the Single-Dose Pharmacokinetics of Once-Daily Cyclobenzaprine Extended-Release 30 mg and Cyclobenzaprine Immediate-Release 10 mg Three Times Daily in the Elderly

Drugs & Aging ◽

10.2165/0002512-200926020-00001 ◽

2009 ◽

Vol 26 (2) ◽

pp. 95-101 ◽

Author(s):

Mona Darwish ◽

Fang Xie

Keyword(s):

Single Dose ◽

Extended Release ◽

Immediate Release ◽

The Elderly ◽

Download Full-text

Comparative Pharmacokinetics of a Once-Daily Tramadol Extended-Release Tablet and an Immediate-Release Reference Product Following Single-Dose and Multiple-Dose Administration

The Journal of Clinical Pharmacology ◽

10.1177/0091270009347673 ◽

2010 ◽

Vol 50 (5) ◽

pp. 544-553 ◽

Author(s):

David Karhu ◽

Caroline Fradette ◽

Maria Alida Potgieter ◽

Maria M. Ferreira ◽

Johann Terblanché

Keyword(s):

Single Dose ◽

Multiple Dose ◽

Extended Release ◽

Reference Product ◽

Immediate Release ◽

Dose Administration ◽

Multiple Dose Administration ◽

Extended Release Tablet ◽

Download Full-text

Comparison of single-dose and multiple-dose pharmacokinetics between two formulations of hydrocodone bitartrate/acetaminophen: immediate-release versus biphasic immediate- release/extended release

Journal of Pain Research ◽

10.2147/jpr.s79578 ◽

2015 ◽

pp. 607 ◽

Author(s):

Krishna Devarakonda ◽

Kenneth Kostenbader ◽

Michael J. Giuliani ◽

James Young

Keyword(s):

Single Dose ◽

Multiple Dose ◽

Extended Release ◽

Immediate Release ◽

Multiple Dose Pharmacokinetics ◽

Hydrocodone Bitartrate

Download Full-text

Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization

Advances in Therapy ◽

10.1007/s12325-019-00904-x ◽

2019 ◽

Vol 36 (6) ◽

pp. 1465-1479 ◽

Author(s):

Bing Ho ◽

Hardik Bhagat ◽

Jason J. Schwartz ◽

Kofi Atiemo ◽

Amna Daud ◽

...

Keyword(s):

Kidney Transplantation ◽

Clinical Outcomes ◽

Resource Utilization ◽

Extended Release ◽

Healthcare Resource ◽

Immediate Release ◽

Healthcare Resource Utilization ◽

Download Full-text

Effect of methylphenidate formulation on attention deficit hyperactivity disorder (ADHD)-patients' adherence to medical treatment. A comparison of Medikinet retard® (extended-release [ER]) once daily and Medikinet® (immediate-release [IR]) twice daily in children and adolescents diagnosed with ADHD

http://isrctn.org/> ◽

10.1186/isrctn93724387 ◽

2012 ◽

Author(s):

Claudia Wachtarz

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Medical Treatment ◽

Children And Adolescents ◽

Attention Deficit ◽

Extended Release ◽

Immediate Release ◽

Hyperactivity Disorder

Download Full-text

Multiple Dose Pharmacokinetics of a New Once Daily Extended Release Tolterodine Formulation Versus Immediate Release Tolterodine

Clinical Pharmacokinetics ◽

10.2165/00003088-200140030-00006 ◽

2001 ◽

Vol 40 (3) ◽

pp. 227-235 ◽

Author(s):

Birgitta Olsson ◽

Johan Szamosi

Keyword(s):

Multiple Dose ◽

Extended Release ◽

Immediate Release ◽

Multiple Dose Pharmacokinetics

Download Full-text

P3-391: PHARMACOKINETICS OF MEMANTINE AND DONEPEZIL AFTER A SINGLE DOSE OF A ONCE-DAILY FIXED-DOSE COMBINATION CAPSULE OF MEMANTINE EXTENDED RELEASE AND DONEPEZIL IN TWO PHASE I TRIALS

Alzheimer s & Dementia ◽

10.1016/j.jalz.2014.05.1485 ◽

2014 ◽

Vol 10 ◽

pp. P772-P773

Author(s):

Ramesh Boinpally ◽

Robert Hofbauer ◽

Laishun Chen ◽

Stephen Zukin ◽

Antonia Periclou

Keyword(s):

Single Dose ◽

Phase I ◽

Extended Release ◽

Fixed Dose Combination ◽

Phase I Trials ◽

Two Phase ◽

Dose Combination

Download Full-text

Efficacy of once-daily extended-release lovastatin as compared to immediate-release lovastatin in patients with hypercholesterolemia

Current Medical Research and Opinion ◽

10.1185/030079903125002612 ◽

2004 ◽

Vol 20 (1) ◽

pp. 13-18 ◽

Author(s):

P. Lukacsko ◽

E. J. Walters ◽

E. I. Cullen ◽

R. Niecestro ◽

L. T. Friedhoff

Keyword(s):

Extended Release ◽

Immediate Release ◽

Download Full-text

P2.153 Once-daily pramipexole extended-release (ER) demonstrated non-inferiority compared to immediate release (IR) tid dosing in early Parkinson's disease

Parkinsonism & Related Disorders ◽

10.1016/s1353-8020(09)70504-8 ◽

2009 ◽

Vol 15 ◽

pp. S131

Author(s):

W. Poewe ◽

P. Barone ◽

R. Hauser ◽

Y. Mizuno ◽

O. Rascol ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Extended Release ◽

Immediate Release ◽

Early Parkinson’S Disease

Download Full-text

Levetiracetam Extended Release as Adjuvant Therapy for the Control of Partial-onset Seizures

Journal of Central Nervous System Disease ◽

10.4137/jcnsd.s4126 ◽

2011 ◽

Vol 3 ◽

pp. JCNSD.S4126

Author(s):

Hasan H. Sonmezturk ◽

Nabil J. Azar

Keyword(s):

Animal Studies ◽

Extended Release ◽

Immediate Release ◽

Release Formulation ◽

Seizure Reduction ◽

Extended Release Formulation ◽

Clonic Seizures

Extended release (XR) formulation of levetiracetam (LEV) is approved by the Food and Drug Administration as an add-on to other antiepileptic drugs (AEDs) for adults with partial onset seizures. This is based on class-I evidence demonstrating significant seizure reduction in once daily dosing. Keppra-XR is marketed with the brand name of Keppra XR since 2008 (UCB Pharma). Its original immediate release (IR) formulation has been in the market since 2000. LEV has a unique molecular structure which is chemically unrelated to existing AEDs. The precise mechanism of action is unknown. Animal studies showed binding to synaptic vesicle protein SV2A, thought to be involved in modulating synaptic neurotransmitter release. LEV-IR is proven effective as adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures and myoclonic seizures. It was shown to be equivalent to carbamazepine as first-line treatment for partial-onset seizures. The extended release formulation added advantages such as better tolerance and increased compliance.

Download Full-text